$HALO
HALOZYME THERAPEUTICS, INC.

2021 Q4 Form 10-Q Financial Statement

#000115903621000050 Filed on November 02, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2021 Q2
Revenue $102.0M $115.8M $136.5M
YoY Change -16.19% 77.34% 147.11%
Cost Of Revenue $21.59M $18.59M $23.02M
YoY Change -17.92% 233.85% 301.01%
Gross Profit $80.42M $97.24M $113.4M
YoY Change 1200.6% 2694.28% 18901.17%
Gross Profit Margin 78.84% 83.95% 83.13%
Selling, General & Admin $13.77M $13.17M $12.32M
YoY Change 32.44% 12.54% 12.26%
% of Gross Profit 17.13% 13.54% 10.86%
Research & Development $10.11M $8.486M $8.069M
YoY Change 36.59% 9.54% -9.85%
% of Gross Profit 12.57% 8.73% 7.11%
Depreciation & Amortization $773.0K $700.0K $800.0K
YoY Change -3.38% -12.5% 0.0%
% of Gross Profit 0.96% 0.72% 0.71%
Operating Expenses $23.88M $21.66M $20.39M
YoY Change -45.82% -13.44% -20.56%
Operating Profit $56.53M $75.59M $93.05M
YoY Change -249.18% 87.56% 214.83%
Interest Expense -$1.724M $1.754M $1.752M
YoY Change -60.82% -64.85% -64.99%
% of Operating Profit -3.05% 2.32% 1.88%
Other Income/Expense, Net $274.0K $221.0K
YoY Change -71.49% -83.31%
Pretax Income $54.81M $74.11M $91.52M
YoY Change -25.12% 104.32% 253.69%
Income Tax -$11.96M $154.2M $58.00K
% Of Pretax Income -21.82% 208.08% 0.06%
Net Earnings $66.77M $216.6M $91.46M
YoY Change -8.74% 498.19% 254.25%
Net Earnings / Revenue 65.46% 186.99% 67.02%
Basic Earnings Per Share $1.53 $0.64
Diluted Earnings Per Share $462.9K $1.48 $0.62
COMMON SHARES
Basic Shares Outstanding 140.8M shares 142.0M shares 142.5M shares
Diluted Shares Outstanding 146.7M shares 147.6M shares

Balance Sheet

Concept 2021 Q4 2021 Q3 2021 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $740.9M $815.9M $755.3M
YoY Change 101.33% 135.33% 95.96%
Cash & Equivalents $118.7M $491.7M $447.0M
Short-Term Investments $622.2M $324.2M $308.3M
Other Short-Term Assets $40.48M $33.30M $32.69M
YoY Change 43.05% 4.39% 11.96%
Inventory $53.91M $55.98M $58.55M
Prepaid Expenses $47.99M $43.32M $42.51M
Receivables $90.98M $112.1M $153.2M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $926.3M $1.017B $999.8M
YoY Change 66.97% 103.91% 99.81%
LONG-TERM ASSETS
Property, Plant & Equipment $6.791M $7.163M $10.13M
YoY Change -6.88% -30.13% -9.28%
Goodwill $0.00
YoY Change
Intangibles $0.00
YoY Change
Long-Term Investments
YoY Change
Other Assets $169.3M $158.5M $15.98M
YoY Change 1059.92% 963.98% 3.1%
Total Long-Term Assets $178.1M $168.1M $26.11M
YoY Change 608.04% 568.9% -1.97%
TOTAL ASSETS
Total Short-Term Assets $926.3M $1.017B $999.8M
Total Long-Term Assets $178.1M $168.1M $26.11M
Total Assets $1.104B $1.185B $1.026B
YoY Change 90.44% 126.21% 94.66%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.541M $3.322M $4.563M
YoY Change -20.07% 667.21% 12.2%
Accrued Expenses $24.44M $18.34M $19.27M
YoY Change 19.32% -28.92% -9.33%
Deferred Revenue $1.746M
YoY Change 0.0%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $89.42M $89.25M $89.17M
YoY Change -77.49%
Total Short-Term Liabilities $117.1M $113.2M $114.3M
YoY Change -72.2% 319.46% 338.2%
LONG-TERM LIABILITIES
Long-Term Debt $787.3M $786.5M $785.6M
YoY Change 99.81% 101.38%
Other Long-Term Liabilities $544.0K $1.609M $2.267M
YoY Change -84.3% -57.58% -51.0%
Total Long-Term Liabilities $787.8M $1.609M $2.267M
YoY Change 22629.34% -57.58% -51.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $117.1M $113.2M $114.3M
Total Long-Term Liabilities $787.8M $1.609M $2.267M
Total Liabilities $904.9M $114.8M $116.5M
YoY Change 113.0% 272.98% 279.54%
SHAREHOLDERS EQUITY
Retained Earnings -$58.91M -$125.7M -$342.3M
YoY Change -87.59% -77.06% -41.39%
Common Stock $256.5M $407.4M $462.0M
YoY Change -59.0% -36.97% -32.89%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $197.0M $281.7M $119.7M
YoY Change
Total Liabilities & Shareholders Equity $1.104B $1.185B $1.026B
YoY Change 90.44% 126.21% 94.66%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2021 Q2
OPERATING ACTIVITIES
Net Income $66.77M $216.6M $91.46M
YoY Change -8.74% 498.19% 254.25%
Depreciation, Depletion And Amortization $773.0K $700.0K $800.0K
YoY Change -3.38% -12.5% 0.0%
Cash From Operating Activities $82.52M $121.7M $36.89M
YoY Change 61.8% 1895.72% 1052.66%
INVESTING ACTIVITIES
Capital Expenditures -$158.0K -$496.0K -$503.0K
YoY Change -90.71% 148.0% 0.6%
Acquisitions
YoY Change
Other Investing Activities -$299.3M -$16.46M -$44.06M
YoY Change -597.19% -44.96% -455.35%
Cash From Investing Activities -$299.5M -$16.95M -$44.57M
YoY Change -611.91% -43.67% -474.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $150.0M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -156.0M -60.07M -44.76M
YoY Change 469.38% 36.83% -429.09%
NET CHANGE
Cash From Operating Activities 82.52M 121.7M 36.89M
Cash From Investing Activities -299.5M -16.95M -44.57M
Cash From Financing Activities -156.0M -60.07M -44.76M
Net Change In Cash -373.0M 44.72M -52.44M
YoY Change -554.28% -165.86% -282.71%
FREE CASH FLOW
Cash From Operating Activities $82.52M $121.7M $36.89M
Capital Expenditures -$158.0K -$496.0K -$503.0K
Free Cash Flow $82.67M $122.2M $37.39M
YoY Change 56.88% 1840.24% 910.49%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei City Area Code
CityAreaCode
858
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.53
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.27
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.39
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.41
dei Entity Central Index Key
EntityCentralIndexKey
0001159036
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--09-30
CY2021Q3 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P12M
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-32335
dei Entity Registrant Name
EntityRegistrantName
HALOZYME THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
88-0488686
dei Entity Address Address Line1
EntityAddressAddressLine1
11388 Sorrento Valley Road
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92121
dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Local Phone Number
LocalPhoneNumber
794-8889
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
dei Trading Symbol
TradingSymbol
HALO
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
140787020 shares
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
491683000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
147703000 USD
CY2021Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
324237000 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
220310000 USD
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.48
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.25
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.28
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.40
CY2021Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13600000 shares
CY2020Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
17600000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13500000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9100000 shares
CY2021Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
112099000 USD
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
97730000 USD
CY2021Q3 us-gaap Inventory Net
InventoryNet
55978000 USD
CY2020Q4 us-gaap Inventory Net
InventoryNet
60747000 USD
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
33302000 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
28274000 USD
CY2021Q3 us-gaap Assets Current
AssetsCurrent
1017299000 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
554764000 USD
CY2021Q3 halo Property Plant And Equipment And Operating Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
9588000 USD
CY2020Q4 halo Property Plant And Equipment And Operating Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
10593000 USD
CY2021Q3 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
15552000 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
14067000 USD
CY2021Q3 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
142481000 USD
CY2020Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
0 USD
CY2020Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
500000 USD
CY2021Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
500000 USD
CY2020Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
500000 USD
CY2021Q3 us-gaap Assets
Assets
1185420000 USD
CY2020Q4 us-gaap Assets
Assets
579924000 USD
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3322000 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1928000 USD
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
18335000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
20483000 USD
CY2021Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2245000 USD
CY2020Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1746000 USD
CY2021Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
89251000 USD
CY2020Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
397228000 USD
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
113153000 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
421385000 USD
CY2021Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
2530000 USD
CY2020Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
4026000 USD
CY2021Q3 us-gaap Long Term Debt
LongTermDebt
786454000 USD
CY2020Q4 us-gaap Long Term Debt
LongTermDebt
0 USD
CY2021Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1609000 USD
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3466000 USD
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
140966000 shares
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
140966000 shares
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
140966000 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
140966000 shares
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
141000 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
135000 USD
CY2021Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
407229000 USD
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
625483000 USD
CY2021Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-14000 USD
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
22000 USD
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-125682000 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-474593000 USD
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
281674000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
151047000 USD
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1185420000 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
579924000 USD
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
115830000 USD
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
65316000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
341307000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
145891000 USD
CY2021Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
18589000 USD
CY2020Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
5568000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
59826000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
17095000 USD
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8486000 USD
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7747000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
25564000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
26856000 USD
CY2021Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
13169000 USD
CY2020Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
11702000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
36549000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
35309000 USD
CY2021Q3 us-gaap Costs And Expenses
CostsAndExpenses
40244000 USD
CY2020Q3 us-gaap Costs And Expenses
CostsAndExpenses
25017000 USD
us-gaap Costs And Expenses
CostsAndExpenses
121939000 USD
us-gaap Costs And Expenses
CostsAndExpenses
79260000 USD
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
75586000 USD
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
40299000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
219368000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
66631000 USD
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
274000 USD
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
961000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
771000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4764000 USD
CY2021Q3 us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
0 USD
CY2020Q3 us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
0 USD
us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
20960000 USD
us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
0 USD
CY2021Q3 us-gaap Interest Expense
InterestExpense
1754000 USD
CY2020Q3 us-gaap Interest Expense
InterestExpense
4990000 USD
us-gaap Interest Expense
InterestExpense
5471000 USD
us-gaap Interest Expense
InterestExpense
15342000 USD
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
74106000 USD
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
36270000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
193708000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
56053000 USD
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-142481000 USD
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
63000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-142232000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
132000 USD
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
216587000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
36207000 USD
us-gaap Net Income Loss
NetIncomeLoss
335940000 USD
us-gaap Net Income Loss
NetIncomeLoss
55921000 USD
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.53
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.27
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.39
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.41
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.48
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.25
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.28
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.40
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
142021000 shares
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
136578000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
140815000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
136575000 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
146690000 shares
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
142081000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
147652000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
139971000 shares
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
216587000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
36207000 USD
us-gaap Net Income Loss
NetIncomeLoss
335940000 USD
us-gaap Net Income Loss
NetIncomeLoss
55921000 USD
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
8000 USD
CY2020Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-640000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-76000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
203000 USD
CY2021Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
0 USD
CY2020Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
13000 USD
us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
-15000 USD
us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
8000 USD
CY2021Q3 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
2000 USD
CY2020Q3 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-7000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
664000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2711000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
215000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
18000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
0 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
3608000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
184000 USD
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
3424000 USD
CY2021Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y4M24D
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
25000 USD
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-9000 USD
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
216597000 USD
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
35547000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
335904000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
56107000 USD
us-gaap Net Income Loss
NetIncomeLoss
335940000 USD
us-gaap Net Income Loss
NetIncomeLoss
55921000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
15694000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
13008000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2224000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2484000 USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
2674000 USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
10540000 USD
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1518000 USD
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-477000 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
631000 USD
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
997000 USD
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
3870000 USD
halo Deferred Rent Payments
DeferredRentPayments
568000 USD
halo Deferred Rent Payments
DeferredRentPayments
759000 USD
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
0 USD
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
525000 USD
us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
20960000 USD
us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
0 USD
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
142481000 USD
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
0 USD
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
-4000 USD
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
-13000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
14369000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
3109000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-5152000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
28338000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
6513000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1567000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-2306000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-40134000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
216924000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
4534000 USD
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
283354000 USD
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
161488000 USD
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
177833000 USD
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
181345000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1299000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
805000 USD
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0 USD
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
861000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-106820000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
19913000 USD
us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
784875000 USD
us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
0 USD
us-gaap Repayments Of Secured Debt
RepaymentsOfSecuredDebt
369064000 USD
us-gaap Repayments Of Secured Debt
RepaymentsOfSecuredDebt
19560000 USD
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
424000 USD
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0 USD
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
189737000 USD
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
109970000 USD
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
8226000 USD
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
50645000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
233876000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-78885000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
343980000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-54438000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
148203000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
120679000 USD
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
492183000 USD
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
66241000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
102000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
531000 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
318000 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1661000 USD
halo Pending Settlementof Common Stock Repurchase
PendingSettlementofCommonStockRepurchase
0 USD
halo Pending Settlementof Common Stock Repurchase
PendingSettlementofCommonStockRepurchase
2502000 USD
us-gaap Stock Issued1
StockIssued1
7865000 USD
us-gaap Stock Issued1
StockIssued1
0 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
119746000 USD
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5399000 USD
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4648000 USD
CY2021Q3 us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
64716000 USD
CY2021Q3 us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
10000 USD
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
216587000 USD
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
281674000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
151047000 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
15694000 USD
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
13104000 USD
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
8226000 USD
us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
189737000 USD
us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
-36000 USD
us-gaap Net Income Loss
NetIncomeLoss
335940000 USD
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
281674000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
105577000 USD
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4220000 USD
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
12546000 USD
CY2020Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 USD
CY2020Q3 us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
58902000 USD
CY2020Q3 us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
-660000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
36207000 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
98988000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
91765000 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
13008000 USD
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
50645000 USD
us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 USD
us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
112472000 USD
us-gaap Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt
AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
-65000 USD
us-gaap Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt
AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
-65000 USD
us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
186000 USD
us-gaap Net Income Loss
NetIncomeLoss
55921000 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
98988000 USD
us-gaap Nature Of Operations
NatureOfOperations
Organization and Business <div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Halozyme Therapeutics, Inc. is a biopharma technology platform company that provides innovative and disruptive solutions with the goal of improving patient experience and outcomes. Our proprietary enzyme, rHuPH20, is used to facilitate the delivery of injected drugs and fluids. We license our technology to biopharmaceutical companies to collaboratively develop products that combine our ENHANZE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> drug delivery</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">technology with the collaborators’ proprietary compounds.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our approved product and our collaborators’ approved products and product candidates are based on rHuPH20, our patented recombinant human hyaluronidase enzyme. rHuPH20 is the active ingredient in our first commercially approved product, Hylenex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> recombinant, (“Hylenex”), and it works by breaking down hyaluronan (or “HA”), a naturally occurring carbohydrate that is a major component of the extracellular matrix in tissues throughout the body such as skin and cartilage. This temporarily increases dispersion and absorption allowing for improved subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other large therapeutic molecules, as well as small molecules and fluids. We refer to the application of rHuPH20 to facilitate the delivery of other drugs or fluids as our ENHANZE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> drug delivery technology (“ENHANZE”). We license the ENHANZE technology to form collaborations with biopharmaceutical companies that develop or market drugs requiring or benefiting from injection via the subcutaneous route of administration. In the development of proprietary intravenous (IV) drugs combined with our ENHANZE technology, data have been generated supporting the potential for ENHANZE to reduce treatment burden, as a result of shorter duration of subcutaneous (SC) administration. ENHANZE may enable fixed-dose SC dosing compared to weight-based dosing required for IV administration, and potentially allow for lower rates of infusion related reactions. ENHANZE may enable more flexible treatment options such as home administration by a healthcare professional or potentially the patient. Lastly, certain proprietary drugs co-formulated with ENHANZE have been granted additional exclusivity, extending the patent life of the product beyond the one of the proprietary IV drug.</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We currently have ENHANZE collaborations with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc. (“Roche”), Baxalta US Inc. and Baxalta GmbH (members of the Takeda group of companies) (“Baxalta”), Pfizer Inc. (“Pfizer”), Janssen Biotech, Inc. (“Janssen”), AbbVie, Inc. (“AbbVie”), Eli Lilly and Company (“Lilly”), Bristol-Myers Squibb Company (“BMS”), Alexion Pharma Holding (AstraZeneca PLC announced the completion of its acquisition of Alexion Pharmaceuticals, Inc. in July 2021) (“Alexion”), argenx BVBA (“argenx”), Horizon Therapeutics plc. (“Horizon”) and ViiV Healthcare (the global specialist HIV company majority owned by GlaxoSmithKline) (“ViiV”). We receive royalties from three of these collaborations, including royalties from sales of one product from the Baxalta collaboration, three products from the Roche collaboration and one product from the Janssen collaboration. Future potential revenues from royalties and fees from ENHANZE collaborations and the sales and/or royalties of our approved products will depend on the ability of Halozyme and our collaborators to develop, manufacture, secure and maintain regulatory approvals for approved products and product candidates and commercialize product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except where specifically noted or the context otherwise requires, references to “Halozyme,” “the Company,” “we,” “our,” and “us” in these notes to the condensed consolidated financial statements refer to Halozyme Therapeutics, Inc. and its wholly owned subsidiary, Halozyme, Inc., and Halozyme, Inc.’s wholly owned subsidiaries, Halozyme Switzerland GmbH and Halozyme Switzerland Holdings GmbH.</span></div>
halo Royalties Received Number Of Collaborators
RoyaltiesReceivedNumberOfCollaborators
3 collaborator
us-gaap Use Of Estimates
UseOfEstimates
Use of EstimatesThe preparation of interim unaudited condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) requires management to make estimates and assumptions that affect the amounts reported in our interim unaudited condensed consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management’s estimates
CY2020Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
500000 USD
CY2021Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
500000 USD
halo Revenue Remaining Performance Obligation Period Of Termination By Written Notice
RevenueRemainingPerformanceObligationPeriodOfTerminationByWrittenNotice
P90D
us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-142500000 USD
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0017
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2021Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
324223000 USD
CY2021Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
37000 USD
CY2021Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
23000 USD
CY2021Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
324237000 USD
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
220220000 USD
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
98000 USD
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
8000 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
220310000 USD
CY2021Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
11 security
CY2021Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
66000000 USD
CY2021Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
23000 USD
CY2021Q3 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0 USD
CY2021Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
286672000 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
220310000 USD
CY2021Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
37565000 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
0 USD
CY2021Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
324237000 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
220310000 USD
CY2021Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
815898000 USD
CY2020Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
367881000 USD
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
115830000 USD
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
65316000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
341307000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
145891000 USD
halo Proceeds From Partner Of License And Collaborative Agreement
ProceedsFromPartnerOfLicenseAndCollaborativeAgreement
221300000 USD
CY2021Q3 halo Accounts Receivableafter Allowancefor Credit Loss Currentexcluding Other Contract Assets
AccountsReceivableafterAllowanceforCreditLossCurrentexcludingOtherContractAssets
112099000 USD
CY2020Q4 halo Accounts Receivableafter Allowancefor Credit Loss Currentexcluding Other Contract Assets
AccountsReceivableafterAllowanceforCreditLossCurrentexcludingOtherContractAssets
90730000 USD
CY2021Q3 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
0 USD
CY2020Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
7000000 USD
CY2021Q3 us-gaap Deferred Revenue
DeferredRevenue
4775000 USD
CY2020Q4 us-gaap Deferred Revenue
DeferredRevenue
5772000 USD
CY2021Q3 us-gaap Deferred Credits And Other Liabilities
DeferredCreditsAndOtherLiabilities
4800000 USD
CY2021Q3 us-gaap Deferred Credits And Other Liabilities
DeferredCreditsAndOtherLiabilities
4800000 USD
CY2021Q3 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
2200000 USD
CY2021Q3 halo Accountsreceivablefromproductsalestocollaborators
Accountsreceivablefromproductsalestocollaborators
18172000 USD
CY2020Q4 halo Accountsreceivablefromproductsalestocollaborators
Accountsreceivablefromproductsalestocollaborators
25198000 USD
CY2021Q3 halo Accountsreceivablefromcollaborators
Accountsreceivablefromcollaborators
30407000 USD
CY2020Q4 halo Accountsreceivablefromcollaborators
Accountsreceivablefromcollaborators
30404000 USD
CY2021Q3 halo Accountsreceivablefromroyalties
Accountsreceivablefromroyalties
59095000 USD
CY2020Q4 halo Accountsreceivablefromroyalties
Accountsreceivablefromroyalties
32098000 USD
CY2021Q3 halo Accountsreceivablefromproductsales
Accountsreceivablefromproductsales
5621000 USD
CY2020Q4 halo Accountsreceivablefromproductsales
Accountsreceivablefromproductsales
4033000 USD
CY2021Q3 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
0 USD
CY2020Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
7000000 USD
CY2021Q3 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
113295000 USD
CY2020Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
98733000 USD
CY2021Q3 halo Allowancefor Distribution Feesand Discounts
AllowanceforDistributionFeesandDiscounts
1196000 USD
CY2020Q4 halo Allowancefor Distribution Feesand Discounts
AllowanceforDistributionFeesandDiscounts
1003000 USD
CY2021Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
112099000 USD
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
97730000 USD
CY2021Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
8109000 USD
CY2020Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
5813000 USD
CY2021Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
21722000 USD
CY2020Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
33738000 USD
CY2021Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
26147000 USD
CY2020Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
21196000 USD
CY2021Q3 us-gaap Inventory Net
InventoryNet
55978000 USD
CY2020Q4 us-gaap Inventory Net
InventoryNet
60747000 USD
CY2021Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
43324000 USD
CY2020Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
35048000 USD
CY2021Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
3156000 USD
CY2020Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
2510000 USD
CY2021Q3 us-gaap Other Assets
OtherAssets
2374000 USD
CY2020Q4 us-gaap Other Assets
OtherAssets
4783000 USD
CY2021Q3 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
48854000 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
42341000 USD
CY2021Q3 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
15552000 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
14067000 USD
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
33302000 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
28274000 USD
CY2021Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
19763000 USD
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
18875000 USD
CY2021Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
12600000 USD
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
11582000 USD
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7163000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7293000 USD
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2425000 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3300000 USD
CY2021Q3 halo Property Plant And Equipment And Operating Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
9588000 USD
CY2020Q4 halo Property Plant And Equipment And Operating Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
10593000 USD
CY2021Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
700000 USD
CY2020Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
800000 USD
CY2021Q3 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
400000 USD
CY2020Q3 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
400000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2200000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2500000 USD
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
1200000 USD
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
1300000 USD
CY2021Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
7652000 USD
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8078000 USD
CY2021Q3 halo Accruedmanufacturingexpenses
Accruedmanufacturingexpenses
2839000 USD
CY2020Q4 halo Accruedmanufacturingexpenses
Accruedmanufacturingexpenses
4535000 USD
CY2021Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
6029000 USD
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
6468000 USD
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
3424000 USD
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
4868000 USD
CY2021Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
19944000 USD
CY2020Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
23949000 USD
CY2021Q3 halo Accrued Liabilities Noncurrent
AccruedLiabilitiesNoncurrent
1609000 USD
CY2020Q4 halo Accrued Liabilities Noncurrent
AccruedLiabilitiesNoncurrent
3466000 USD
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
18335000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
20483000 USD
CY2021Q3 halo Operating Lease Accretion Of Liability
OperatingLeaseAccretionOfLiability
100000 USD
CY2020Q3 halo Operating Lease Accretion Of Liability
OperatingLeaseAccretionOfLiability
100000 USD
CY2021Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
500000 USD
CY2020Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
500000 USD
halo Operating Lease Accretion Of Liability
OperatingLeaseAccretionOfLiability
300000 USD
halo Operating Lease Accretion Of Liability
OperatingLeaseAccretionOfLiability
400000 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
1500000 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
1700000 USD
CY2021Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
600000 USD
CY2020Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
800000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
2000000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
2500000 USD
CY2019Q4 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
447300000 USD
CY2021Q1 us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
369100000 USD
CY2021Q1 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
370200000 USD
CY2021Q1 us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
9080000.00 shares
us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
21000000 USD
us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
21000000 USD
CY2021Q3 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
895936000 USD
CY2021Q1 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
460000000 USD
CY2021Q3 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
20231000 USD
CY2021Q1 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
10211000 USD
CY2021Q3 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
875705000 USD
CY2021Q1 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
449789000 USD
CY2021Q3 us-gaap Debt Instrument Fair Value
DebtInstrumentFairValue
893419000 USD
CY2021Q1 us-gaap Debt Instrument Fair Value
DebtInstrumentFairValue
861738000 USD
CY2020Q2 us-gaap Repayments Of Debt
RepaymentsOfDebt
2930000 USD
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5399000 USD
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4220000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
15694000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13008000 USD
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5399000 USD
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4220000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
15694000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13008000 USD
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
32500 shares
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
34700 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
700000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1500000 shares
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P4Y8M12D
CY2020Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P4Y10M24D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P4Y8M12D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y2M12D
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0066
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0089
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0022
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0031
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0036
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0089
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0022
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0167
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2019Q4 us-gaap Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
550000000 USD
CY2019Q4 us-gaap Stock Repurchase Program Period In Force1
StockRepurchaseProgramPeriodInForce1
P3Y
CY2019 us-gaap Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
11100000 shares
CY2019 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
200000000 USD
CY2019 us-gaap Treasury Stock Acquired Average Cost Per Share
TreasuryStockAcquiredAverageCostPerShare
18.03
CY2020 us-gaap Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
6500000 shares
CY2020 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
150000000 USD
CY2020 us-gaap Treasury Stock Acquired Average Cost Per Share
TreasuryStockAcquiredAverageCostPerShare
23.05
CY2020Q4 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
21700000 USD
CY2021Q1 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
75000000 USD
CY2021Q1 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
75000000 USD
CY2021Q2 us-gaap Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
500000 shares
CY2021Q1 us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
1775945 shares
CY2021Q1 us-gaap Treasury Stock Acquired Average Cost Per Share
TreasuryStockAcquiredAverageCostPerShare
42.89
CY2021Q1 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
76179000 USD
CY2021Q2 us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
1037547 shares
CY2021Q2 us-gaap Treasury Stock Acquired Average Cost Per Share
TreasuryStockAcquiredAverageCostPerShare
47.05
CY2021Q2 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
48842000 USD
CY2021Q3 us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
1562613 shares
CY2021Q3 us-gaap Treasury Stock Acquired Average Cost Per Share
TreasuryStockAcquiredAverageCostPerShare
41.40
CY2021Q3 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
64717000 USD
us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
4376105 shares
us-gaap Treasury Stock Acquired Average Cost Per Share
TreasuryStockAcquiredAverageCostPerShare
43.35
us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
189738000 USD
CY2021Q1 halo Treasury Stock Acquired Fee Cost Per Share
TreasuryStockAcquiredFeeCostPerShare
0.02
CY2021Q2 us-gaap Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
500000 shares
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
216587000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
36207000 USD
us-gaap Net Income Loss
NetIncomeLoss
335940000 USD
us-gaap Net Income Loss
NetIncomeLoss
55921000 USD
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
142021000 shares
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
136578000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
140815000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
136575000 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
146690000 shares
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
142081000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
147652000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
139971000 shares

Files In Submission

Name View Source Status
0001159036-21-000050-index-headers.html Edgar Link pending
0001159036-21-000050-index.html Edgar Link pending
0001159036-21-000050.txt Edgar Link pending
0001159036-21-000050-xbrl.zip Edgar Link pending
ex31110qq32021.htm Edgar Link pending
ex31210qq32021.htm Edgar Link pending
ex3210qq32021.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
halo-20210930.htm Edgar Link pending
halo-20210930.xsd Edgar Link pending
halo-20210930_cal.xml Edgar Link unprocessable
halo-20210930_def.xml Edgar Link unprocessable
halo-20210930_g1.jpg Edgar Link pending
halo-20210930_g2.jpg Edgar Link pending
halo-20210930_htm.xml Edgar Link completed
halo-20210930_lab.xml Edgar Link unprocessable
halo-20210930_pre.xml Edgar Link unprocessable
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending